Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.

@article{LundbyChristensen2016MetforminVP,
  title={Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.},
  author={Louise Lundby-Christensen and Lise Tarnow and Trine Well\ov Boesgaard and S\oren S\ogaard Lund and Niels Wiinberg and Hans Perrild and Thure Krarup and Ole Snorgaard and Birthe Gade-Rasmussen and Birger Thorsteinsson and Michael Einar R\oder and Elisabeth R Mathiesen and Tonny J Jensen and Henrik Vestergaard and Christoffer Hedetoft and Leif Breum and Elsebeth Duun and Simone Bjerregaard Sneppen and Oluf Pedersen and Bianca Hemmingsen and Bendix Carstensen and Sten Madsbad and Christian N Gluud and J\orn Wetterslev and Allan Vaag and Thomas Peter Almdal},
  journal={BMJ open},
  year={2016},
  volume={6 2},
  pages={e008376}
}
OBJECTIVE To assess the effect of metformin versus placebo both in combination with insulin analogue treatment on changes in carotid intima-media thickness (IMT) in patients with type 2 diabetes. DESIGN AND SETTING Investigator-initiated, randomised, placebo-controlled trial with a 2 × 3 factorial design conducted at eight hospitals in Denmark. PARTICIPANTS AND INTERVENTIONS 412 participants with type 2 diabetes (glycated haemoglobin (HbA1c) ≥ 7.5% (≥ 58 mmol/mol); body mass index >25 kg/m2… CONTINUE READING